Search
Close this search box.

IGC Pharma's novel approach to

Alzheimer's Disease

Reach out to learn more about IGC-AD1's Phase 2b trial for agitation in dementia due to Alzheimer's

Alzheimer's disease affects over 55 million individuals worldwide 1

In treating agitation, which affects 40-80% of individuals with Alzheimer’s disease2, IGC-AD1 has shown promising results.

Before After

Drag to discover more

Impacting Lives: Our Work Matters

With no known cure for Alzheimer’s disease, our drugs have the potential to change lives. 

Million
0
Americans with Alzheimer’s disease in 20243
Million
0
Americans with Alzheimer’s disease by 20603

5th Leading

Cause of death among
Americans aged 65+3

Trillon
$ 0

Expected cost of Alzheimer’s and dementia by 2050 (in 2024 dollars) if no treatment or cure is found3

From the CEO's desk:
Vertical integration

Periodic updates and perspectives on various aspects of our business.

Science Spotlight

Welcome to “Science Spotlight” – your exclusive platform for insights into neurological disorders. Dr. Juan Manuel Orjuela and the IGC Pharma scientific team bring you in-depth articles on conditions such as Alzheimer’s disease, offering comprehensive updates on treatment and understanding their impact on individuals and families. Explore the roles of caregivers and dynamics within affected families. Stay informed with our latest article.

Psychosis in Parkinson

Parkinson's awareness month

Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common symptoms involve visual or auditory hallucinations, distorted perception, and experiences. More challenging symptoms may occur in the form of delusions, which often cause agitation, aggressiveness, and affect the quality of life of the patient and their families.

Psychosis in Parkinson

Parkinson's awareness month ____________________________ Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common symptoms involve visual or auditory hallucinations, distorted perception, and experiences. More challenging symptoms may occur in the form of delusions, which often cause agitation, aggressiveness, and affect the quality of life of the patient and their families.

IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer’s Research

By: Faith Ashmore Benzinga …

IGC Pharma Advances in Alzheimer’s Research from Pre-clinical Studies to Phase Two Trials with its Novel Therapy Candidate IGC-AD1

By:   Faith Ashmore …

The Synesthetic Brain

Synesthesia is a complex experience that involves perceiving the elements of the world with more than one sense. By integrating the knowledge of neuroscience with these aspects of perception, scientists have been able to map synchronous patterns of activation in brain regions that do not entirely relate to the stimulus nature. The intriguing nature of this process invites people to be more aware of what they can perceive in a world saturated with external information.

Artificial Intelligence and Alzheimer’s Disease

In Alzheimer's disease research, the integration of artificial intelligence (AI) enables researchers to uncover patterns and biomarkers faster, facilitating earlier diagnosis and personalized therapies. Embracing these new technologies not only enhances the understanding of AD but also propels the development of innovative treatments for this complex neurological condition.

Musical Memories and Alzheimer’s Disease

Music therapy can improve the quality of life for patients with Alzheimer’s disease by reducing agitation and depression while also improving mood and social interaction. Music serves as a powerful tool for improving communication and emotional well-being. It is particularly effective in facilitating a connection with their past and sense of identity.

Latest News

Investing in the Future: Building Brighter Lives for Children

At IGC Pharma, we recognize our commitment to patients, caregivers, and their families, including children. Explore our programs dedicated to children.

  1. World Health Organization, Dementia, Key facts, 15 March 2023.
  2. Van der Mussele S et al. Agitation-associated behavioral symptoms in MCI and Alzheimer’s dementia. Aging Ment Health 2014;19(3):247–57.
  3. Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5)